ReviewNeuroimaging clinics of North America2020
Magnetoencephalography for Schizophrenia.
Review in Neuroimaging clinics of North America, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Revolutionizing Pediatric Neurophysiology With Magnetoencephalography.Psychophysiology · 2026Review
- From bench to bedside: Overview of magnetoencephalography in basic principle, signal processing, source localization and clinical applications.NeuroImage. Clinical · 2024Review
- Self-Regulatory Neuronal Mechanisms and Long-Term Challenges in Schizophrenia Treatment.Brain sciences · 2023Review
- A Brief Introduction to Magnetoencephalography (MEG) and Its Clinical Applications.Brain sciences · 2022Review
- Multiscale Weighted Permutation Entropy Analysis of Schizophrenia Magnetoencephalograms.Entropy (Basel, Switzerland) · 2022Article
- Neuroimaging in schizophrenia: A review article.Frontiers in neuroscience · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Schizophrenia (Sz) is a chronic mental disorder characterized by disturbances in thought (such as delusions and confused thinking), perception (hearing voices), and behavior (lack of motivation). The lifetime prevalence of Sz is between 0.3% and 0.7%, with late adolescence and early adulthood, the peak period for the onset of psychotic symptoms. Causal factors in Sz include environmental and genetic factors and especially their interaction. About 50% of individuals with a diagnosis of Sz have lifelong impairment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.